Liposome coated stents: A method to deliver drugs to the site of action and improve stent blood-compatibility

Journal of Liposome Research

Volumn 16, Issue 3, 2006, Pages 303-309

  Antimisiaris, S G ^a   Koromila, G ^a   Michanetzis, G ^b   Missirlis, Y F ^b  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Controlled release; Dexamethasone; Haemocompatibility; Heparin; Liposome; Stent

Indexed keywords

DEXAMETHASONE; HEPARIN; LIPOSOME;

BLOOD COMPATIBILITY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG RELEASE; PRIORITY JOURNAL;

BLOOD; DRUG DELIVERY SYSTEMS; LIPOSOMES; STENTS;

EID: 33748490046     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.1080/08982100600848579     Document Type: Conference Paper

References (6)

1. Antimisiaris, S. G., Siablis, D., Liatsikos, E., Kalogeropoulou, C., Tsota, I., Tsotas, V., Karnabatidis, D., Fatouros, D. G., Barbalias, G. A. (2000). Liposome-coated metal stents: An in vitro evaluation of controlled-release modality in the ureter. J. Endourology 14:743-747.
2. Kallinteri, P., Antimisiaris, S. G., Tsota, I., Kalogeropoulou, C., Karnabatidis, D., Siablis, D. (2002). Dexamethasone incorporating liposomes: An in vitro study of their applicability as a slow release delivery system of dexamethasone from covered metallic stents. Biomaterials, 23:4819-4826.
3. Koromila, G., Michanetzis, G., Missirlis, Y. F., Antimisiaris, S. G. (2006). Heparin incorporating liposomes as a delivery system of heparin from PET-covered metallic stents: Effect on haemocompatibility. Biomaterials, 2525-2533.
4. Magnani, A., Busi, E., Barbucci, R. (1994). In-situ ATR-FTIR studies of protein adsorption on polymeric materials. Effectiveness of surface heparinization. J Mater Sci-Mater M. 5:839-843.
5. Schwartz, R. S., Nicolas, A., Chronos N. A., Virmani, R. (2004). Preclinical restenosis models and drug-eluting stents: Still important, still much to learn. JACC 44:1373-1385.
6. Thomas, A. C., Campbell, J. H. (2004). Targeted delivery of heparin and LMWH using a fibrin antibody prevents restenosis. Atherosclerosis, 176:73-81.